Danish researchers analyzed data from over 77,000 people using anti-obesity medications without diabetes. They found 52 percent stopped treatment within one year.
Eighteen percent quit within three months, 31 percent within six months, and 42 percent after nine months.
GLP-1 Drugs Aid Weight Loss But Require Commitment
Ozempic and Wegovy belong to GLP-1 receptor agonists. These medications mimic hormones that reduce appetite, helping people lose weight.
Professor Reimar W. Thomsen explained, “Patients lose all appetite control benefits if they stop taking these drugs.” He stressed long-term use remains essential.
Demographics and Side Effects Influence Dropouts
Researchers found younger adults under 30 were 48 percent more likely to quit than adults aged 45 to 59. Men also abandoned treatment more often.
People living in low-income areas quit 14 percent more than wealthier residents. Prior use of psychiatric or gastrointestinal drugs may indicate side effects like nausea or vomiting triggered discontinuation.
Cost Barriers Affect Adherence
In Denmark, a month’s supply of Ozempic costs up to €313 without type 2 diabetes coverage. In Germany, the same supply costs around €120.
Researchers argue high prices may prevent consistent access, especially for patients with limited financial resources.
Public Health Implications
Thomsen highlighted that these drugs reduce risks of heart disease, cancer, and addiction. Half of European adults live with overweight or obesity.
He emphasized the importance of targeting interventions that encourage adherence. Doing so improves treatment effectiveness, overall health outcomes, and quality of life.
Upcoming Presentation
The study’s findings will appear at the European Association for the Study of Diabetes annual meeting in Vienna. Researchers hope the data will guide policies supporting patients who benefit most from GLP-1 medications.
